Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
- Features Alzheimer’s Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. -
PURCHASE, N.Y., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released the second “Conversations” video podcast, featuring a virtual fireside discussion with neuroscience experts who share their perspective on clinical data recently presented at the 2022 CTAD conference in San Francisco, and implications for future Alzheimer’s disease clinical research.
Episode 2: "Building on Amyloid Lowering: Key Insights from Recent Data and Prospects for Complementary Therapeutic Approaches" is moderated by Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer and head of R&D, and features a conversation between:
- Christopher H. van Dyck, M.D.
Yale University School of Medicine Professor of Psychiatry, Neurology, and Neuroscience;
Director of the Yale School of Medicine Division of Aging and Geriatric Psychiatry;
Director of the Alzheimer's Disease Research Center; and
- Anton P. Porsteinsson, M.D.
University of Rochester School of Medicine and Dentistry William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine;
Director of the Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Discussion topics include:
- Reaction to the lecanemab CLARITY clinical study data presentation;
- Emerging consensus on the value of targeting amyloid oligomers/protofibrils to achieve clinical benefit; and
- Prospects for a multi-pronged approach to modulate amyloid and protect neurons from neurotoxic forms of Aβ to further slow Alzheimer’s disease progression.
Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at email@example.com. We’d love to hear your thoughts!
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash and financial resources and our clinical development plans, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, our ability to secure new (and retain existing) grant funding, our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities Exchange Commission. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Cognition Therapeutics, Inc.
Aline Sherwood (media)